Fact-check: Ohio State's 90-second answer to what a GLP-1 agonist is

What the video covers

A physician at Ohio State Wexner Medical Center answers one question in 87 seconds: what is a GLP-1 receptor agonist and how does it work. The answer is that the drug mimics a peptide hormone the body already makes, binds to receptors in the brain and gastrointestinal tract, and acts on appetite, fullness and blood-sugar regulation at the same time. The speaker closes by noting that semaglutide's cardiovascular benefit appears to be separate from its weight effect and is still being studied.

What it gets right

The mechanism is stated correctly and in the right order of importance. GLP-1 receptors are expressed in the hypothalamus and brainstem as well as in the gut and pancreas, and the labelled clinical pharmacology for semaglutide describes reduced appetite, reduced energy intake and delayed gastric emptying alongside glucose-dependent insulin secretion (Wegovy label, section 12). The line that "there's not one single mechanism" is the honest version of a story that is often told as if the drug only makes you feel full.

The cardiovascular point is also right. In SELECT, semaglutide 2.4 mg reduced the composite of cardiovascular death, non-fatal heart attack and non-fatal stroke from 8.0 percent to 6.5 percent over a mean of 39.8 months in 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes (PubMed 37952131). The benefit appeared early and did not track weight loss cleanly, which is why the video says the mechanism is "still being explored".

What it leaves out or overstates

It is a definition, not a briefing, so the gaps are the things a definition cannot hold. There is no number for how much weight people lose: STEP 1 found a mean 14.9 percent reduction at 68 weeks against 2.4 percent on placebo (PubMed 33567185). There are no side effects, no boxed warning about thyroid C-cell tumours in rodents, no mention that the drug must be continued to keep the effect, and no mention of cost.

One sentence deserves a caveat. The speaker says people with obesity "sometimes produce lower levels of this hormone". Studies of post-meal GLP-1 secretion in people with obesity are mixed; some find blunted responses, others find none. The drugs work because they deliver a receptor agonist at doses far above physiological GLP-1, not because they are correcting a deficiency. Treat that line as a simplification rather than the reason the class works.

Where to go next

The full incretin story with diagrams is on FormBlends Science. The next video in this playlist, from Harvard Medical School, supplies the trial numbers this one omits. If you are comparing agents, GLP-1s Explained has one page per molecule with label doses and approval dates. For a plain-language introduction to tirzepatide, read the FormBlends guide at formblends.com. Compounded semaglutide and tirzepatide, including what FormBlends dispenses, are not FDA approved and are not interchangeable with the brand products the trials studied.